



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

ADVANCE QLD INDUSTRY FELLOWSHIP WINS

EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to advise that, in a collaboration with the University of Queensland (UQ) and Metro South Hospital & Health Service, two key members of the UQ electromagnetic imaging algorithm team have won prestigious Advance QLD Industry Research Fellowships.

These fellowships include a total of \$360,000, over 3 years, in Advance QLD funding towards their respective roles in EMVision’s brain scanner development program. The fellows will be physically co-located between UQ (applicant), EMVision (partner) and Metro South Health (partner). These Fellows will add capacity and allow accelerated approaches to image reconstruction. The funding agreement for these fellowships is anticipated to be executed shortly.

EMVision’s CEO, Dr Ron Weinberger, commented “We are thrilled with the state government’s recognition and support of our transformational brain scanner development program. These highly competitive fellowship wins will help offset the cost to EMV for key team members and coincide with the Company’s ongoing recruitment of key roles in its product development team focussed on building devices for regulatory approval and commercial release. We continue to pursue non-dilutive opportunities that makes sense, ensuring the best use of our funds”.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision’s CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics’ (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years’ experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company’s platform technology and launched their breakthrough product ‘Trophon’ globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in

transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

About Advance Queensland Industry Research Fellowships

The Queensland Government established the Advance Queensland Industry Research Fellowships program to provide funding assistance to outstanding early and mid-career researchers to undertake research at a Queensland-based agency that will benefit Queensland. The program assists in attracting and keeping the best and brightest research minds in Queensland, and builds Queensland's capacity to conduct innovative research and development in partnership with industry.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.